REGENXBIO Inc. $RGNX Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 4.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,037,248 shares of the biotechnology company’s stock after purchasing an additional 185,223 shares during the quarter. JPMorgan Chase & Co. owned 7.98% of REGENXBIO worth $38,959,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its position in REGENXBIO by 2,247.7% in the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after buying an additional 594,161 shares during the last quarter. Invenomic Capital Management LP bought a new stake in shares of REGENXBIO during the 3rd quarter worth $4,120,000. Integral Health Asset Management LLC boosted its stake in shares of REGENXBIO by 57.1% during the 3rd quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $10,615,000 after acquiring an additional 400,000 shares in the last quarter. 22NW LP grew its holdings in shares of REGENXBIO by 38.1% in the 2nd quarter. 22NW LP now owns 923,679 shares of the biotechnology company’s stock worth $7,583,000 after acquiring an additional 255,000 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of REGENXBIO by 151.1% in the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock worth $2,961,000 after acquiring an additional 249,156 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Stifel Nicolaus upped their target price on REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, December 19th. Barclays started coverage on REGENXBIO in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price target on the stock. HC Wainwright cut their price objective on REGENXBIO from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Morgan Stanley decreased their target price on shares of REGENXBIO from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Finally, UBS Group restated an “overweight” rating and set a $18.00 price target on shares of REGENXBIO in a report on Tuesday, February 10th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

REGENXBIO Stock Down 3.1%

REGENXBIO stock opened at $8.10 on Friday. REGENXBIO Inc. has a 12 month low of $5.03 and a 12 month high of $16.19. The stock has a market cap of $418.04 million, a P/E ratio of -2.15 and a beta of 1.08. The company’s fifty day simple moving average is $10.39 and its 200-day simple moving average is $11.43.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.29). REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%. The firm had revenue of $30.34 million for the quarter, compared to analyst estimates of $45.48 million. On average, equities research analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

Insider Buying and Selling at REGENXBIO

In other news, insider Steve Pakola sold 5,124 shares of REGENXBIO stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $10.35, for a total transaction of $53,033.40. Following the completion of the sale, the insider directly owned 247,926 shares in the company, valued at $2,566,034.10. The trade was a 2.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.79% of the stock is owned by company insiders.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.